Dr Alan Prem Kumar and his team, have discovered a way to turn off the “master switch” driving aggressive triple-negative breast cancer. By targeting the DP103 gene with a drug called RX-5902, the team achieved a massive 90% reduction in tumour size in lab models while sparing healthy cells.

This breakthrough could lead to highly personalised, targeted treatments for patients facing this aggressive disease. Kudos to Dr Alan Prem Kumar and everyone in the research team for their dedication to translating laboratory science into life-saving hope.

Click here to read the full feature in The Straits Times.

Click here to read publication.